Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 17/20 | 0.56 |
| ▸ | GSK3B | P49841 | 12/20 | 0.56 |
| ▸ | WNT1 | P04628 | 7/20 | 0.56 |
| ▸ | CLK2 | P49760 | 4/20 | 0.56 |
| ▸ | CLK3 | P49761 | 4/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.44 |
| ▸ | FOXO1 | Q12778 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23916692 | 0.84 | DYRK1A (0.57) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL23916168 | 0.82 | DYRK1A (0.56) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL23916731 | 0.81 | DYRK1A (0.54) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL23916131 | 0.76 | DYRK1A (0.62) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL23048650 | 0.75 | DYRK1A (0.61) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL23048816 | 0.74 | DYRK1A (0.56) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL19546802 | 0.73 | DYRK1A (0.64) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL19516591 | 0.72 | DYRK1A (1.00) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL19540255 | 0.72 | DYRK1A (0.65) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL19540415 | 0.71 | GSK3B (0.75) | DYRK1AGSK3BWNT1CLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3892276-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AS WNT INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |